Brought to you by 
Merck, Pierre Fabre Medicament sign oncology deal
Aug 2004
Executive Summary
Merck and Pierre Fabre Medicament signed a research, development, and licensing agreement involving Pierre Fabre's recombinant humanized monoclonal antibody F50035, which targets the insulin-like growth factor (IGF-1) receptor; IGF-1 is overexpressed in various cancers including colon, breast, and prostate.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Pierre Fabre Medicament sign oncology deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice